[Form 3] Can-Fite BioPharma Ltd. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. director Yoseph Bornstein filed an initial Form 3 reporting his holdings of stock options to purchase the company’s ordinary shares. The filing lists four option grants with different exercise prices, vesting schedules, and expiration dates.

One grant covers 200 underlying shares at an exercise price of $241.47, fully vested and expiring on June 22, 2031. Two additional grants each relate to 2,166 underlying shares, with exercise prices of $25.21 and $26.56 and expirations on April 30, 2033 and May 7, 2034, respectively; portions of these are already vested and the rest vest in specified quarterly installments. A larger grant covers 16,000 underlying shares at an exercise price of $2.18, expiring on January 25, 2030, with all of these options vesting in sixteen equal quarterly installments from April 25, 2026 through January 25, 2030.

The footnotes explain that, to qualify for certain Israeli tax benefits under Section 102, plan securities are held in the name of a trustee, and that the exercise prices were originally denominated in New Israeli Shekels and converted to U.S. dollars using a Bank of Israel exchange rate of 3.106 NIS per USD reported on March 11, 2026.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bornstein Yoseph

(Last) (First) (Middle)

C/O CAN-FITE BIOPHARMA LTD.

26 BEN GURION STREET

(Street)

RAMAT GAN 5257346

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Can-Fite BioPharma Ltd. [ CANF ]

3a. Foreign Trading Symbol
[CANF.TA]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(2)	06/22/2021	06/22/2031	Ordinary Shares	200(2)	$241.47(3)	D
Options to Purchase Ordinary Shares(1)(4)	08/01/2023	04/30/2033	Ordinary Shares	2,166(4)	$25.21(4)	D
Options to Purchase Ordinary Shares(1)(5)	08/07/2024	05/07/2034	Ordinary Shares	2,166(5)	$26.56(5)	D
Options to Purchase Ordinary Shares(1)(6)	04/25/2026	01/25/2030	Ordinary Shares	16,000(6)	$2.18(6)	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.

2. These options are fully vested and exercisable as of the date hereof.

3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 750, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.

4. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,489 options are vested, and the remaining 677 options vest in five equal quarterly installments beginning 05/01/2026 and ending 05/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

5. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 947 options are vested, and the remaining 1,219 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

6. The exercise price of this option, originally denominated in NIS in the amount of NIS 6.767, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein, none are vested, and all the 16,000 options vest in sixteen equal quarterly installments beginning 04/25/2026 and ending 01/25/2030 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Yoseph Bornstein	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did Yoseph Bornstein report in his Form 3 for Can-Fite (CANF)?

Yoseph Bornstein reported existing holdings of stock options to purchase Can-Fite ordinary shares. The Form 3 lists four option grants with specific exercise prices, expiration dates, and vesting schedules, establishing his initial derivative ownership position as a director.

How many Can-Fite ordinary shares are covered by Yoseph Bornstein’s reported options?

The Form 3 shows separate option grants over 200, 2,166, 2,166, and 16,000 underlying ordinary shares. Each grant has its own exercise price, vesting terms, and expiration date, detailing the structure of his derivative holdings rather than any recent transaction.

What are the key exercise prices and expirations of Bornstein’s Can-Fite options?

Reported exercise prices are $241.47, $25.21, $26.56, and $2.18 per share. Corresponding expiration dates are June 22, 2031, April 30, 2033, May 7, 2034, and January 25, 2030, defining when each option grant can be exercised before it lapses.

How do Yoseph Bornstein’s Can-Fite option grants vest over time?

One 200-share grant is fully vested. For the 2,166-share grants, portions are already vested and the remainder vest in quarterly installments between May 1, 2026 and May 7, 2028. The 16,000-share grant vests in sixteen quarterly installments from April 25, 2026 through January 25, 2030.

Why are Can-Fite options in Bornstein’s Form 3 held through a trustee?

The footnotes state Israeli Section 102 tax rules require securities issued under the company’s share option plans to be registered in a trustee’s name. This structure is designed to enable certain tax benefits for the employee while still reflecting the director’s beneficial option holdings.

How were Can-Fite option exercise prices converted from NIS to USD in this Form 3?

Several option exercise prices were originally set in New Israeli Shekels and then presented in U.S. dollars. The conversion used a Bank of Israel exchange rate of 3.106 NIS per USD, based on the rate reported on March 11, 2026, as explained in the footnotes.